AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda

AbbVie’s Skyrizi, which is already making inroads in Crohn’s disease, has clinched a win in another inflammatory bowel disease (IBD). 

Skyrizi as an induction therapy helped significantly more patients with moderate to severe ulcerative colitis achieve clinical remission compared with placebo in a phase 3 trial, AbbVie said Thursday.